Biograstims sikkerhed og effekt er undersøgt i randomiserede, kontrollerede fase III- forsøg hos patienter med brystcancer, lungecancer og non- Hodgkin- lymfom.
The efficacy and safety of Biograstim has been assessed in randomised, controlled phase III studies in breast cancer, lung cancer and Non-Hodgkin-Lymphoma.